PDS Biotechnology Corporation announced that Spencer Brown has joined PDS Biotech as Senior Vice President, General Counsel. Mr. Brown has extensive legal affairs and compliance experience with leading biotechnology, healthcare and pharmaceutical companies. Prior to joining PDS Biotech, Mr. Brown held the position of Senior Vice President, Legal Affairs and Compliance Officer at Aclaris Therapeutics Inc. Prior to Aclaris, Mr. Brown served as Senior Counsel at GE Healthcare.

Mr. Brown holds a Bachelor of Arts from Princeton University and a Doctor of Law from the University of Pennsylvania Carey Law School. Additionally, PDS Biotech granted Mr. Brown nonstatutory stock options to purchase 150,000 shares of PDSs common stock as a material inducement to his employment with PDS Biotech in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotechs 2019 Inducement Plan, as amended. PDS Biotechs 2019 Inducement Plan, as amended, provides for the granting of equity awards to new employees of PDS Biotech.

The stock option award has an exercise price of $4.22, the closing price of PDS Biotechs common stock on June 2, 2022. The option award vests over a four-year period, with one-quarter of the shares vesting on the first anniversary of the grant date (June 2, 2023) and then monthly over the following 36 months, subject to continued employment with the company through the applicable vesting dates.